fbpx

2021 Bourses d’été pour étudiants en recherche

Les candidatures pour les bourses d'études 2021 sont maintenant ouvertes. La date limite de soumission des candidatures est le 19 février 2021.

Image is not available

Psoriasis and Beyond

Nous sommes heureux d'annoncer le lancement de l'enquête internationale Psoriasis and Beyond, en partenariat avec IFPA. L'enquête vise à découvrir comment le psoriasis et le rhumatisme psoriasique peuvent avoir un impact sur la vie des individus.

Pendant cette période d'incertitude, nous partagerons des nouvelles et des informations relatives aux risques et aux impacts de COVID-19. Veillez à rester à jour et à prendre soin de vous.

Image is not available
Image is not available

COVID-19

#PsoIntimate

Joignez-vous à nous le jour de la Saint-Valentin pour le lancement de notre campagne #PsoIntimate. Une campagne qui vise à discuter de l’impact que le psoriasis peut avoir sur les relations intimes.

previous arrow
next arrow
Shadow
Slider

The Canadian Association of Psoriasis Patients is pleased to announce the winners of this year’s studentships in psoriatic disease. Congratulations to all of you!

Andreea Damian

Andreea Damian

Université de Toronto

Directrice de recherche : Dr Lihi Eder, Women’s College Research Institute, Toronto, Ontario

 

Titre : [traduction] « Déterminer l’incidence et les facteurs de risque des évènements thromboemboliques chez les personnes atteintes de psoriasis et d’arthrite psoriasique »

Summary: (disponible seulement en anglais)

Psoriasis is an inflammatory skin condition that affects 1-3% of the population. Additionally, 20- 30% of patients with psoriasis go on to develop inflammation of their joints termed psoriatic arthritis (PsA). These diseases are collectively referred to as Psoriatic Disease (PsD). Due to the chronic systemic inflammation in PsD, there are a number of secondary complications that may develop. One such complication is venous thromboembolism (VTE), a blood clot in the venous blood system of the body that can be life-threatening.

Although there are many causes of VTE, systemic inflammation has been reported to increase the risk of developing VTE. However, there is limited knowledge on the risk of developing VTE in patients with PsD. This topic is important as recent studies highlighted a potential risk for VTE associated with a class of medications approved for the treatment of PsA.

Our study aims to determine the incidence and risk factors for developing VTE in patients with PsD by utilizing data from a large, multi-centre, longitudinal cohort of over 5000 patients with psoriasis and PsA. Identifying predisposing factors for VTE in this patient population could identify high-risk patients that will benefit from preventative interventions and better selection of treatment.

 

Amy Du

Amy (Xiaoyang) Du

Université de l’Alberta

Directeur de recherche : Dr Robert Gniadecki, Centre universitaire de dermatologie, Université de l’Alberta, Edmonton, Alberta

 Titre : [traduction] « Prédiction des résultats cliniques du psoriasis à l’aide de l’apprentissage machine »

Summary: (disponible seulement en anglais)

Psoriasis is a chronic and inflammatory skin disease with a number of possible associated health problems, including heart disease, diabetes, psychosocial disorders, and cancer. Psoriasis is extremely common, with approximately 1.7% of the Canadian population affected to some degree. Previously considered exclusively a skin disease, it is now understood that psoriasis has a profound impact on patient overall patient health.

The unprecedented success of biologic therapy in psoriasis has changed the landscape of treatment in this disease. But, despite the vast amount of data on the efficacy of biologics, therapeutic decision-making is still based on trial-and-error, with some psoriasis patient registries documenting that 20-50% of patients experience gradual losses in response to treatment and require switches to different drugs. The long-term efficacy of biologics is, to a certain extent, predictable and depends on complex interactions between numerous variables.

Unfortunately, statistical analyses have failed to reveal strong predictors for this loss in efficacy, and clinicians and patients remain burdened with the need to constantly change medications to maintain control. Machine learning techniques are often able to detect such complex patterns and are being increasingly used with success in predicting future trajectories of patients’ health in diverse areas of medicine.

Such an approach would assist physicians in selecting the best treatment methods, save patients’ time, reduce treatment costs and improve the quality of treatment overall by reducing the amount of trial-and-error in the treatment process. As such, our study aims to examine whether machine learning can aid in predicting long-term responses to biologics in psoriasis through analysis of data of psoriasis patients from an updated psoriasis patient registry cohort.

  

Finstad Alexandra

Alexandra Finstad

Université d’Ottawa

Directeur de recherche : Dr Raed Alhusayen, Sunnybrook Research Institute, Toronto, Ontario

 Titre : [traduction] « Tendances en soins du psoriasis : une étude en population »

Summary: (disponible seulement en anglais)

Psoriasis is a chronic inflammatory skin disease affecting an estimated 1 million Canadians, with the prevalence of psoriasis on the rise. Treatment methods for psoriasis have commonly included topical therapies, ultraviolet light, and systemic therapies. Most cases of psoriasis are managed in an outpatient setting; however, some cases may require inpatient management. In recent years, with the introduction of biologics, the treatment and monitoring of psoriasis has evolved.

Despite its rising prevalence and psoriasis care being a rapidly evolving field, relatively little is known about the landscape of psoriasis care, including information on treating physicians. The purpose of this study is to investigate the demographic and economic burden of psoriasis on Ontario’s population and health care system. A particular focus will be made on providers of psoriasis care, types of visits, and differences in the presentation of psoriasis in various health care settings. A retrospective population-based analysis will be performed on all physicians licensed to practice in Ontario from April 1, 2007, to March 31, 2017, who saw patients for psoriasis. The study will span a total of 10 years, providing a longitudinal image of trends in psoriasis care. Data will be obtained from IntelliHealth, a database operated by the Ontario Ministry of Health and Long-Term Care.

We will explore trends in the number of visits for psoriasis, differences in the settings of psoriasis care, the economic cost of care, and the average cost per visit over time. The information collected in this study will provide insight into physician practice patterns and patient access to psoriasis care. This data can be used to facilitate health care planning and to optimize health care resources.

 

Jacqueline Lai

Jacqueline Lai

Université Western

Directeur de recherche : Dr Vinod Chandran, University Health Network, Toronto Psoriatic Disease Research Program, Toronto, Ontario

Titre : [traduction] « Études sur le pronostic et les biomarqueurs pour le psoriasis et arthrite psoriasique »

Summary: (disponible seulement en anglais)

Psoriasis is a common immune-mediated skin condition found in 3% of individuals. About 30% of individuals with psoriasis develop a specific form of arthritis called psoriatic arthritis (PsA) which is associated with disability, decreased quality of life, and increased mortality risk.

Despite the availability of biologic therapies, about 40% of patients have persistent inflammation. Histone deacetylase inhibitors (HDACi) are a new class of drugs that are used in cancer treatment and may have promise in PsA due to their anti-inflammatory effects. However, this field is relatively new, and studies are still ongoing with no known or new HDACi made ready yet for the psoriatic market.

This project aims to determine if HDACi can inhibit the release of inflammatory markers from cells that are important in PsA and psoriasis such as immune and skin cells while assessing their toxicity to these cells. This investigation will ultimately allow for the development of new treatments to improve the quality of life of patients with PsA and psoriasis.


 

2T3 Lytvyn Yuliya new photoYuliya Lytvyn

Université de Toronto

Directeur de recherche : Dr Jensen Yeung, Université de Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario

 Titre : [traduction] « Le traitement par brodalumab est-il efficace et sûr chez les personnes atteintes de psoriasis en plaques modéré à grave qui ont été traités sans succès par le secukinumab ou l’ixekizumab ? Une étude rétrospective à l’Université de Toronto »

Summary: (disponible seulement en anglais)

: More than 125 million people worldwide are living with psoriasis, 90% of which have a form known as plaque psoriasis. Patients present with raised, red patches with a silvery white build-up of dead skin found on the scalp, knees, elbows and lower back. Such skin presentations are a result of chronic auto-immune inflammation, which also increases the risk of developing a number of debilitating health comorbidities such as psoriatic arthritis, infections, cancers, gastrointestinal, kidney and cardiometabolic diseases. Unfortunately, there is no definitive cure, but therapies are available to treat the symptoms.

Due to a large heterogeneity between patients, not all treatments are equally efficacious, which often results in a frustrating cycle of medication trial and error for the patient. This leaves a large number of symptomatic patients incurring costs for ineffective medication, decreased productivity, lowered quality of life and the burden of being at risk for developing the dreadful comorbidities.

Some of the medications effective in a proportion of patients with moderate to severe plaque psoriasis include secukinumab and ixekizumab. These act by selectively inhibiting interleukin-17A (IL-17A), an inflammatory marker that is a subset of a larger IL-17 family. Recently, a new medication called brodalumab was approved for treatment in this patient group. This medication inhibits an upstream receptor for IL-17, which effects a larger number of inflammatory markers in the IL-17 family suggesting a potential and not yet studied advantage over secukinumab and ixekizumab.

Accordingly, the aim of this study is to measure the safety and efficacy of brodalumab in comparison to secukinumab and/or ixekizumab in the treatment of moderate to severe psoriasis in the real-world clinical practice at the outpatient dermatology clinics. The ultimate goal of this study is to guide physicians as to how to prescribe and monitor responses to the currently available IL-17 inhibitors with varying mechanisms of action. The results of this study have the potential to situate brodalumab as an efficacious drug for treatment of plaque psoriasis in patients that were previously unsuccessfully treated with secukinumab and/or ixekizumab.

abbvie Baush fixedJanssen 3c RGBLeoLogo   ucb

L’Association canadienne des patients atteints de psoriasis est heureuse d’annoncer les gagnantes et gagnants des bourses d’été en recherche sur le psoriasis. Nous vous félicitons !

Alexandra Finstad 

Université de Toronto

Directeur de recherche : Dr Raed Alhusayen

Projet : [traduction] Enquête sur le risque de malignité chez les personnes âgées atteintes de psoriasis : le choix du traitement a-t-il une incidence sur le risque futur de malignité ?

Titre du résumé : [traduction] Enquête sur le risque de malignité chez les personnes âgées atteintes de psoriasis : le choix du traitement a-t-il une incidence sur le risque futur de malignité ?

Lay Abstract: (disponible seulement en anglais)

Psoriasis is a chronic inflammatory multisystem disease that affects the regeneration of skin cells. It commonly presents on the elbows, knees, and scalp, but can occur anywhere on the human body. Affecting approximately 2-3% of the world’s population (World Health Organization), psoriasis is not just a physical disease, but also has an important emotional impact on those whom it affects. As there currently exists no cure, effective treatment is critical. However, there is still much research that needs to be done in regard to the long-term effects of different psoriasis treatment options, including the potential risk of malignancy. This, coupled with research that has shown that immune-suppressive treatment can be associated with an increased risk of malignancy, led us to explore the potential connection between psoriasis treatment and increased risk of malignancy. As there are many different treatment options for psoriasis, the purpose of our study is to investigate and identify those that may carry an increased risk of future malignancy in order to protect psoriasis patients and to provide the best care possible. Thus, our research question is: Does psoriasis treatment affect one’s future risk of malignancy? Due to data restrictions, our study will focus on outcomes in the elderly population (defined as those 70 years and older). In order to explore our research question, we will be conducting a retrospective cohort study looking at the risk of malignancy in elderly patients with psoriasis compared to the general population, and we will be conducting subgroup  analysis based on psoriasis treatment and the presence of psoriatic arthritis. We will also conduct further analysis by exploring the risk of specific types of malignancies in psoriasis patients including selective solid organ and hematologic malignancies. Through conducting this study, we hope to explore and uncover the potential association between psoriasis and its different treatments on the subsequent risk of developing a malignancy, with the hope of reducing this risk.
 

Amy Du

Université de l’Alberta

Directeur de recherche : Dr Robert Gniadecki

Projet : [traduction] Imagerie corporelle tridimensionnelle des lésions psoriasiques

Titre du résumé : [traduction] Imagerie corporelle 3D des lésions psoriasiques

Lay Abstract: (disponible seulement en anglais)

Psoriasis is a chronic, relapsing skin disease that affects as much as 11.4% of adults in some countries. It can have a significant negative impact on both the physical
and psychosocial well-being of affected patients. With its ever-increasing incidence and prevalence in the world, the need for high quality, standardized monitoring and treatment of psoriasis is immense.
 
The landscape of the human skin takes a very complex form, with its properties depending on a variety of patient factors (e.g. age, gender, body morphology) and its location on the body (e.g. abdomen vs. underarm vs. hand). While a crucial part of
psoriasis treatment is tracking lesion progression in a consistent and standardized manner, the aforementioned qualities of skin can make it difficult for dermatologists to achieve this in an objective manner. Traditionally, psoriasis progression has been
monitored by the Psoriasis Area and Severity Index (PASI) score, a measurement tool that can be subject to variability between raters and even within the same rater. In literature, more objective photographic techniques to estimate the region of skin
conditions have been proposed. While these techniques are simple, they are not reliable for mapping large or irregular skin lesions. 
 
As such, our study aims to use novel machine learning techniques and algorithms (i.e. artificial intelligence) to detect, map, and measure the surface area of skin lesions on a 3D model of the entire human body in the context of psoriasis. New techniques in model-based human pose and shape estimation, as well as 3D reconstruction of the body will be applied to create an accurate body skin map.
 
 

Christine Eun Byeol Jo,

Université d’Ottawa

Directeur de recherche : Dr Jensen Yeung

Projet : [traduction] L’efficacité et l’innocuité du certolizumab pegol pour le traitement du psoriasis en plaques modéré à grave : comparaison entre les personnes atteintes naïves TNF-α et celles expérimentées en pratique réelle

Titre du résumé : [traduction] Est-ce qu’une seconde chance vaut la peine ? L’efficacité et de l’innocuité du certolizumab pegol pour le traitement du psoriasis en plaques modéré à grave après l’échec d’un autre anti-TNF-α

Lay Abstract : (disponible seulement en anglais)

With heightened understanding of the pathogenesis of psoriasis, many biologics have been introduced to market and are now considered the mainstay treatment. One of the earliest classes of biologics that have significantly improved patient management are anti-TNF-α. However, as individual patient response to different biologics varies, not everyone responds adequately to all biologics. Therefore, biologic switching has become a common practice. Deciding on the next optimal biologic agent remains a clinical challenge with no guidelines currently available. In the case of anti-TNF-α, while some studies state it is unnecessary to switch to a different mechanism of action, others warn of a lower response rate of a second anti-TNF-α in patients who were previously unresponsive. Certolizumab pegol (CZP) is the newest anti-TNF-α that has been approved for moderate-to-severe psoriasis by Health Canada in August 2018. Surprisingly, randomized controlled trials (RCT) showed equal efficacy between anti-TNF-α naive and experienced patients, proving CZP to be a promising option even after previous anti-TNF-α failure. However, this information is limited to RCT results which due to strict inclusion and exclusion criteria may lack generalizability to the real world. For the first time ever, our team will examine the real-world efficacy and safety of switching to CZP for treatment of moderate-to-severe plaque psoriasis at two academic sites in Toronto (Women’s College Hospital and Sunnybrook Health Sciences Centre). Results from the study will significantly help patients and physicians in real-world practice by providing greater understanding of its expected outcome for patients placed in this potentially challenging clinical situation.
 

Clare Sheen

Université de Toronto

Directrice de recherche : Dr Dafna Gladman

Projet : [traduction] Examen de la régulation génétique et épigénétique de la CXCL10 dans la conversion du psoriasis à l’arthrite psoriasique

Titre du résumé : [traduction] Comprendre la régulation des protéines inflammatoires chez les personnes atteintes de psoriasis qui développent l’arthrite psoriasique

Lay Abstract: (disponible seulement en anglais)

Psoriatic arthritis (PsA) is an inflammatory arthritis associated that develops in approximately one third of psoriasis patients. Currently, it is difficult for family physicians and dermatologists to recognize PsA, and as a result, 30-40% of individuals who have the disease are undiagnosed. The difficulty in recognizing PsA stems from the lack of a diagnostic test to identify which psoriasis patients have it, or predict which are susceptible to developing it in the future. A blood biomarker test is urgently needed to help physicians identify PsA at an early stage, so that patients can be treated in an appropriate and timely manner.
 
Our laboratory has done extensive work to identify the blood protein CXCL10 as a potential biomarker of PsA in patients with psoriasis. We found that blood CXCL10 levels are higher in PsA patients compared to psoriasis patients without arthritis. Moreover, CXCL10 levels are higher in psoriasis patients who later develop PsA compared to patients who never develop PsA. CXCL10 is involved in attracting immune cells to the joints.
 
In other diseases, it is known that CXCL10 levels in the blood is influenced by genes. The hypothesis of this study is that these genes will be found more frequently in PsA patients compared to psoriasis patients, and that the presence of certain genes will correlate with blood CXCL10 levels. This study will use laboratory and computational methods to examine how the genes are related to CXCL10 levels. This knowledge will help us understand CXCL10’s role in the development of PsA and whether the genes regulating its levels can also serve as blood biomarkers of future PsA onset.
 

Khalad Maliyar

Université de Toronto

Directrice de recherche : Dr Melinda Gooderham

Projet : [traduction] Efficacité, innocuité et modifications du traitement de Guselkumab en monothérapie pour le psoriasis en plaques modéré à grave : une étude rétrospective canadienne.

Titre du résumé : [traduction] Efficacité, innocuité et modifications du traitement de Guselkumab en monothérapie pour le psoriasis en plaques modéré à grave : une étude rétrospective canadienne.

Lay Abstract: (disponible seulement en anglais)

Psoriasis is a common, chronic, inflammatory skin disease that affects approximately 3% of individuals living in Western countries. Patients with psoriasis suffer from a myriad of health sequelae such as psoriatic arthritis, gastrointestinal diseases, and cardiometabolic diseases. Furthermore, psoriasis has a profoundly detrimental effect on patient’s quality of life, psychological well-being, mental health, and work productivity. There are a wide range of genetically inherited, environmental, endocrine, and immunological factors that contribute to the incidence and severity of psoriasis in each patient. Sadly, there is currently no definitive cure for psoriasis. There are therapies available that can help attenuate the gravity of the symptoms, but due to the idiosyncratic variation amongst patients, not all treatments are equally as efficacious.
 
Recently, a new medication called TremfyaTM (guselkumab) was approved for the treatment of moderate to severe plaque psoriasis. TremfyaTM is the first biologic treatment that selectively inhibits interleukin-23 (IL-23), one of the main pro-inflammatory proteins believed to mediate the inflammatory processes seen in plaque psoriasis. The development of this new targeted therapy offers patients an auxiliary option to manage their plaque psoriasis. Results of recent clinical trials that have led to the approval of TremfyaTM by Health Canada, have demonstrated that it is both safe and provides significant improvement in skin lesions. Notwithstanding encouraging results, there is currently a paucity in the scientific literature of how safe and effective guselkumab treatment is in real-world clinical practice. Accordingly, the aim of this study is to measure the safety, efficacy, and treatment changes of guselkumab in the treatment of moderate to severe psoriasis in an outpatient, community dermatologic clinic. The ultimate goal of this study is to guide physicians as to how to appropriately prescribe and monitor TremfyaTM. The results of the study have the possibility of situating TremfyaTM as an efficacious staple drug used for the treatment of plaque psoriasis.
 
 

 

L’Association canadienne des patients atteints de psoriasis est heureuse d’annoncer les gagnantes et gagnants des bourses d’été en recherche sur le psoriasis. Nous vous félicitons !

Arvin Ighani

Université de Toronto

Directeur de recherche : Dr Jensen Yeung

Projet : [traduction] « Une étude prospective évaluant l’innocuité, l’efficacité et l’impact sur la qualité de vie de la photothérapie par ultraviolets B à bande étroite dans le traitement du psoriasis : des données probantes pour les décisions de financement public et de politique de soins de santé

Titre du résumé : [traduction] La photothérapie pour le traitement du psoriasis justifie-t-elle un financement public supplémentaire au Canada ? Une évaluation de l’efficacité, de l’innocuité et de l’impact sur la qualité de vie de la photothérapie par ultraviolets B à bande étroite pour soutenir des politiques de soins de santé fondées sur des données probantes.

Lay Abstract: (disponible seulement en anglais)

Psoriasis is a skin condition which is thought to affect approximately 125 million people worldwide. Many of these individuals have moderate-to-severe psoriasis that requires treatment beyond first-line topical management. Although many effective oral and injectable therapies exist for its management, they can be associated with severe side-effects, large financial burden, inconvenient monitoring, and uncomfortable routes of delivery. Given these setbacks, physicians would ideally first consider NB-UVB phototherapy as a treatment option in suitable candidates before recommending systemic or biologic therapies because of its excellent safety profile and potentially successful clinical reduction of psoriasis. However, the lack of accessibility to phototherapy centers and long wait times for treatment often impede patients from seeking this therapy. The issues surrounding  accessibility for phototherapy are partly driven by the lack of physician compensation for prescribing these treatments and the unmet need for increased government funding to maintain phototherapy centers. Currently, there are few high-quality research studies that clearly demonstrate the efficacy and impact on quality of life of NB-UVB phototherapy for psoriasis patients in the context of specific dosing regimens with qualified nursing staff that use optimal dosing regimens to achieve successful psoriasis clearance. The goal of our research is to
conduct a high-quality prospective study that clearly demonstrates the efficacy, safety, and impact on quality of life of NB-UVB phototherapy. This data can then be used to guide government policymaking and potentially be used to justify increased funding for phototherapy centers across the country, leading to greater patient accessibility, optimal dosing regimens for patients, and ultimately better clearance of psoriasis with minimal side effects for patients who have been unsuccessful with other treatments.
 

Ryan Lewinson

Université de Calgary

Directrice de recherche : Dr Cheryl Barnabe

Projet : [traduction] « La biomécanique dans la pathogenèse de l’arthrite psoriasique »

Titre du résumé : [traduction] « La biomécanique dans la pathogenèse de l’arthrite psoriasique »

Lay Abstract: (disponible seulement en anglais)

Psoriasis is an inflammatory skin disease where patients develop itchy scaling skin plaques. Psoriasis skin lesions are thought to sometimes form due to mechanical stress applied to the skin, a process called the “Koebner-phenomenon,” named after the German dermatologist Heinrich Koebner who discovered the process. In other words, if a person has psoriasis, new lesions can form on previously normal skin when it is traumatized by mechanical stress. This process is not well understood, but appears to be related to inflammatory signaling in the skin.
 
Interestingly, there has recently been a proposed “deep-Koebner” phenomenon as well that affects joints rather than skin. This process may be important for patients with psoriatic arthritis (PsA) – a condition where the patient has skin psoriasis and also painful, destructive inflammation to joints and tendons. The deep-Koebner phenomenon is proposed to also occur in response to mechanical stimuli, where a joint exposed to abnormal mechanical loading may be susceptible to then developing joint inflammation in PsA.
 
There has been very little research on the topic of the deep-Koebner phenomenon in PsA, but clarifying this process could hold important clues in understanding the pathogenesis of PsA and potentially reveal new treatment targets and disease prevention strategies. Our aims in this project are to conduct a review of the literature to identify all documented laboratory and clinical studies assessing the role of biomechanics in the development of PsA, which includes human data, as well as data from tissue and animal modelling experiments. In so doing, we hope to identify the current knowledge gaps in understanding the deep-Koebner phenomenon and propose new hypotheses for focused study in the future. This study will provide an overview of what is already known about the deep-Koebner phenomenon, as well as provide an important first step in identifying future directions in basic science, engineering and clinical research for PsA.
 
 

Daniel Pau

Université Toronto Western

Directrice de recherche : Dr Dafna Gladman

Projet : [traduction] « Évaluation de l’atteinte de la colonne vertébrale pour l’arthrite psoriasique »

Titre du résumé : [traduction] Les radiographies du bas du dos peuvent-elles être utilisées pour pronostiquer l’arthrite psoriasique (APs) chez les personnes atteintes de psoriasis ?

Lay Abstract: (disponible seulement en anglais)

Psoriasis is a chronic inflammatory skin disease affecting 0.5 to 11.4 percent of adults worldwide. There is an increasing understanding of systemic comorbid conditions in patients with psoriasis. Diseases reported to occur at a higher frequency include cardiovascular disease, hypertension, diabetes, and autoimmune disorders. Between 30 to 40 percent of psoriasis cases will develop psoriatic arthritis (PsA). PsA impacts the quality of life, work function, and increases mortality risk due to the strong association with many other diseases. There is a growing need to begin earlier diagnosis of PsA to prevent these downstream effects. Although back disease is recognized as a domain of PsA, patients with PsA do not complain of a lot of pain and the only way to detect the presence of back disease is by radiographs. We have previously found that the modified Stokes Ankylosing Spondylitis Score is most sensitive to change in PsA. We now plan to complete reading of radiographs of PsA patients in our clinic, determine whether the presence of degenerative disc disease affects the scores, and discern whether anti-TNF agents reduce radiographic progression of spine disease as they do for peripheral joint disease.
 

Priya Dhir

Université Toronto Western

Directrice de recherche : Dr Dafna Gladman

Projet : [traduction] « L’interleukin-17 comme biomarqueur pour prédire l’APs »

Titre du résumé : [traduction] Biomarqueurs pour prédire l’arthrite psoriasique

Lay Abstract: (disponible seulement en anglais)

Psoriasis is a common immune-mediated skin condition affecting 2-3% of the population.  Almost a third of individuals with psoriasis develop psoriatic arthritis (PsA), a chronic inflammation of assorted joints throughout the body. The severity of the disease varies but is often associated with disability, decreased quality of life, and increased mortality risk. Studies indicate that 30-40% of patients with psoriasis have undiagnosed PsA. The lack of a definitive laboratory test for PsA may contribute to this statistic. Presently, rheumatologists mainly rely on clinical assessment and radiographic techniques to diagnose PsA. These tests detect the disease after joint damage has already taken place. Our project aims to find reliable biomarkers that can help in early detection of PsA. This study will help understand the source of these differences in the blood of PsA patients in order to strengthen their utility as markers of PsA. Early detection allows early treatment, which is promising for prevention of joint damage and improving quality of life for patients. Furthermore, the project will help shed light on the pathophysiology of PsA.
 

Ahmed Mourad

Université de l’Alberta

Directeur de recherche : Dr Robert Gniadecki

Projet : [traduction] « Comment pouvons-nous améliorer les résultats de traitement du psoriasis ? Un examen systématique et une méta-analyse de la durée d’efficacité des médicaments biologiques dans le traitement du psoriasis »

Titre du résumé : [traduction] Comment pouvons-nous améliorer les résultats de traitement du psoriasis ? Un examen systématique et une méta-analyse de la durée d’efficacité des médicaments biologiques dans le traitement du psoriasis.

Lay Abstract: (disponible seulement en anglais)

Psoriasis is a chronic skin condition that has a profound negative impact on patient wellbeing and quality of life. Psoriasis is often difficult to treat, especially when it involves the majority of the body. Biologic medication has been shown to be very helpful in treating psoriasis because they interfere with the body’s immune system to decrease the cytokines (cell messengers) that are involved in psoriasis. There are multiple biologics currently approved to treat psoriasis. These biologics show varying degrees of effect according to the scientific studies, but no study to date has summarized the data in a way useful for clinicians to use. Once patients discontinue their biologic medication, their psoriasis recurs. It is therefore important for patients to remain on their biologic therapy for as long as they can safely tolerate it. Drug survival is defined as the time until discontinuation of a drug. It is a real-world substitute measure of effectiveness, safety, and improved disease control for patients with psoriasis. Biologics with better drug survivals are more effective and have better safety profiles. The purpose of this study is to summarize the current literature on the drug survival of the different biologic therapies used in psoriasis and create a numerical pooled result through a meta-analysis (statistical analysis of the currently available studies). The studied biologics will be compared against each other by calculating a summarized statistical measure called a hazard ratio. It is hypothesized that we will  identify certain biologics that consistently have longer drug survivals among the various studies. This study will be a powerful resource for clinicians to refer to when making treatment decisions for their patients with psoriasis.
 

Le programme de bourses d’été du ACPP offre un financement aux étudiantes et étudiants de premier cycle et ainsi qu’à celles et ceux inscrits dans un programme de santé. L’objectif est de leur permettre de mener à bien des projets de recherche d’été liés aux maladies psoriasiques sous la supervision de chercheurs établis. Cette possibilité de financement encourage l’intérêt pour les maladies psoriasiques chez les chercheurs en début de carrière, soutient un environnement qui offre un encadrement solide et contribue à la connaissance générale des maladies psoriasiques.

Les candidatures doivent être déposées en février de chaque année pour des projets de recherche qui se dérouleront au cours de l’été de la même année. Nous encourageons les demandes provenant de partout au Canada qui reflètent les quatre piliers en recherche : biomédicale, clinique, sur les systèmes et services de santé et sur la santé des populations.

Le programme de bourses d’été de l’ACPP a été lancé en 2016. Nous vous invitons à consulter les travaux de recherche réalisés par les boursières et boursiers de l’ACPP.

Boursières et boursiers 2020

Boursières et boursiers 2019

Boursières et boursiers 2018

Boursières et boursiers 2017

Boursières et boursiers 2016

 

Prix de l’application des connaissances

Les boursières et boursiers de l’ACPP sont également admissibles pour un prix d’application des connaissances. À la fin de la période de financement, ils sont invités faire la demande d’une bourse de voyage de 1 000 dollars. Cette bourse vise à les aider à présenter les résultats de leurs recherches lors de conférences nationales ou internationales. Pour demander ce financement, les boursières et boursiers doivent envoyer une lettre de demande accompagnée de la confirmation d’acceptation de leur présentation à toute conférence pertinente.

Si vous avez des questions concernant le programme, veuillez nous contacter à ou par téléphone au 1-877-505-2772.